Cell Therapy News

Cell Therapy News is an online resource dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.

Subscribe|Follow Us On

ERC Awards Proof of Concept Grants to 182 Researchers

July 6, 2026

[The European Research Council] The European Research Council (ERC) has announced the names of its grantees to be awarded the Proof of Concept Grants. Funding for this first round of 2026, worth €27.3 million, will go to 182 researchers.

FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease

July 6, 2026

[US FDA] The US FDA issued a supplemental approval for Casgevy (exagamglogene autotemcel) for patients aged two years and older with either sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent β thalassemia.

FDA Grants Full Approval to Engineered Cell Therapy for Treating Rare Sarcoma

July 6, 2026

[Memorial Sloan Kettering Cancer Center] The US FDA has granted full approval for the immunotherapy afamitresgene autoleucel (Tecelra®, also known as afami-cel) for the treatment of patients with  synovial sarcoma.

FATP2-Mediated Lipid Metabolism Enhances Chimeric Antigen Receptor T-Cell Therapy Resistance in B-Cell Acute Lymphoblastic Leukemia

July 6, 2026

[Leukemia] Through genome-wide CRISPR/Cas9 screening of CAR-sensitive TP53-wildtype and CAR-resistant TP53-mutated CD19 + B-cell acute lymphoblastic leukemia (B-ALL) cell lines, researchers found the fatty acid transport protein 2 (FATP2) is a leukemia-intrinsic mechanism of CAR-T resistance in TP53-mutant B-ALL.

The Evolving Role of Cytokines for CAR-T Cell Manufacturing and Beyond

July 6, 2026

[Nature Biomedical Engineering] The authors ilustrate the evolving use of cytokines, reveal non-standardized clinical CAR-T cell manufacturing parameters, and summarize preclinical and next-generation concepts, which may improve manufacturing efficiency, cost-effectiveness and therapeutic outcomes.

Advances and Prospects in Cell Therapy for Cancer: Explorations from T Cells to Stem Cells

July 6, 2026

[Signal Transduction and Targeted Therapy] In vivo engineering technologies that directly deliver CAR genes in situ are emerging as promising approaches to lower costs and simplify manufacturing by bypassing complex ex vivo procedures.

Linperlisib Enhances MUC1-Tn CAR T Cell Efficacy by Inhibiting EGR1/DUSP2 Axis to Prevent CAR T Cell Exhaustion

July 6, 2026

[Leukemia] Investigators confirmed Mucin1-Thomsen-nouvelle (MUC1-Tn) protein expression in T cell acute lymphoblastic leukemia cell lines and primary patient-derived bone marrow cells and subsequently developed MUC1-Tn-targeted CAR T cells.

Circumventing Ewing Sarcoma Tumor Microenvironment Resistance by IL1RAP CAR-Modified TGFβ1-Imprinted Natural Killer Cells in Combination with IL-15 Agonist and Anti-GD2 Antibody

July 6, 2026

[Journal for Immunotherapy of Cancer] Scientists found that anti-IL1RAP-CAR-NK cells significantly and specifically enhanced NK cytotoxicity in vitro and decreased tumor growth and lung metastasis in vivo against IL1RAP+ Ewing sarcoma.

CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance

July 6, 2026

[Cancer Immunology Research] The authors evaluated the O-glycosylated IIICS domain of fibronectin as a CAR T cell target.

Engineering Interferon-γ-Enhanced Chimeric Antigen Receptor Macrophages via Lipid-Assisted Polymeric Nanoparticles for Cancer Immunotherapy

July 6, 2026

[ACS Nano] Scientists developed macrophage-preferential ionizable cationic lipid-assisted polymeric nanoparticles to co-deliver mRNAs encoding interferon-γ and a CAR molecule, enabling in vivo engineering of CAR-macrophages with a sustained M1-like phenotype.

Intravesical Mesothelin-Based CAR T Cells Targeting MUC16 Effectively Control Bladder Cancer in Preclinical Models

July 6, 2026

[Journal of Experimental Medicine] Investigators identified and validated MUC16 as a clinically relevant target for bladder cancer (BCa), noting enriched expression in tumors recalcitrant to existing therapies. They engineered a second-generation mesothelin-based CAR and demonstrated robust activity across multiple BCa cell lines and patient-derived tumor organoids.

Five ERC Grants Awarded to TUM Researchers

June 30, 2026

[Technical University of Munich] A potential new diabetes target, next-generation thrombosis sensors, and an immune-activating cancer therapy are among five Technical University of Munich (TUM) research projects awarded European Research Council (ERC) Proof of Concept grants to advance promising discoveries toward real-world applications.

Published since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.